Galmed Pharmaceuticals Ltd.
GLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $4 | $13 | $27 |
| G&A Expenses | $3 | $4 | $5 | $6 |
| SG&A Expenses | $3 | $4 | $5 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$15 | $0 | $0 |
| Operating Expenses | $6 | -$7 | $18 | $33 |
| Operating Income | -$6 | $7 | -$18 | -$33 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$14 | -$0 | $0 |
| Pre-Tax Income | -$8 | -$7 | -$18 | -$32 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$7 | -$19 | -$32 |
| % Margin | – | – | – | – |
| EPS | -8.08 | -30.05 | -11.08 | -19.48 |
| % Growth | 73.1% | -171.2% | 43.1% | – |
| EPS Diluted | -8.08 | -29.95 | -11.08 | -19.48 |
| Weighted Avg Shares Out | 1 | 0 | 2 | 2 |
| Weighted Avg Shares Out Dil | 1 | 0 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$7 | -$18 | -$33 |
| % Margin | – | – | – | – |